Mark Pruzanski Intercept Pharmaceuticals, Inc. (ICPT) insider trading activity

Mark Pruzanski is Director of INTERCEPT PHARMACEUTICALS, INC.. Currently has a direct ownership of 0 shares of ICPT, which is worth approximately $0. The most recent transaction as insider was on Nov 08, 2023, when has been sold 618,894 shares (Common Stock) at a price of $19.0 per share, resulting in proceeds of $11,758,986. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Mark Pruzanski Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 08 2023	SELL Disposition due to a tender of shares in a change of control transaction	$11,758,986 $19.0 p/Share	618,894 Reduced 100.0%	0 Common Stock
Nov 30 2021	SELL Payment of exercise price or tax liability	$65,691 $17.21 p/Share	3,817 Reduced 0.61%	618,894 Common Stock
Nov 30 2021	BUY Grant, award, or other acquisition	$105,635 $17.21 p/Share	6,138 Added 0.98%	622,711 Common Stock
Oct 29 2021	SELL Payment of exercise price or tax liability	$64,355 $16.86 p/Share	3,817 Reduced 0.62%	616,573 Common Stock
Oct 29 2021	BUY Grant, award, or other acquisition	$103,487 $16.86 p/Share	6,138 Added 0.98%	620,390 Common Stock
Sep 30 2021	SELL Payment of exercise price or tax liability	$56,668 $14.85 p/Share	3,816 Reduced 0.62%	614,252 Common Stock
Sep 30 2021	BUY Grant, award, or other acquisition	$91,120 $14.85 p/Share	6,136 Added 0.98%	618,068 Common Stock
Aug 31 2021	SELL Payment of exercise price or tax liability	$56,911 $14.91 p/Share	3,817 Reduced 0.62%	611,932 Common Stock
Aug 31 2021	BUY Grant, award, or other acquisition	$91,518 $14.91 p/Share	6,138 Added 0.99%	615,749 Common Stock
Jul 30 2021	SELL Payment of exercise price or tax liability	$65,958 $17.28 p/Share	3,817 Reduced 0.62%	609,611 Common Stock
Jul 30 2021	BUY Grant, award, or other acquisition	$106,065 $17.28 p/Share	6,138 Added 0.99%	613,428 Common Stock
Jun 30 2021	SELL Payment of exercise price or tax liability	$76,206 $19.97 p/Share	3,816 Reduced 0.62%	607,290 Common Stock
Jun 30 2021	BUY Grant, award, or other acquisition	$122,536 $19.97 p/Share	6,136 Added 0.99%	611,106 Common Stock
May 28 2021	SELL Payment of exercise price or tax liability	$63,477 $16.63 p/Share	3,817 Reduced 0.63%	604,970 Common Stock
May 28 2021	BUY Grant, award, or other acquisition	$102,075 $16.63 p/Share	6,138 Added 1.0%	608,787 Common Stock
Apr 30 2021	SELL Payment of exercise price or tax liability	$75,500 $19.78 p/Share	3,817 Reduced 0.75%	502,649 Common Stock
Apr 30 2021	BUY Grant, award, or other acquisition	$121,410 $19.78 p/Share	6,138 Added 1.2%	506,466 Common Stock
Mar 31 2021	SELL Payment of exercise price or tax liability	$84,427 $23.08 p/Share	3,658 Reduced 0.73%	500,328 Common Stock
Mar 31 2021	BUY Grant, award, or other acquisition	$141,619 $23.08 p/Share	6,136 Added 1.2%	503,986 Common Stock
Feb 26 2021	SELL Payment of exercise price or tax liability	$59,370 $21.66 p/Share	2,741 Reduced 0.55%	497,850 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	$132,949 $21.66 p/Share	6,138 Added 1.21%	500,591 Common Stock
Jan 29 2021	SELL Payment of exercise price or tax liability	$96,593 $35.24 p/Share	2,741 Reduced 0.55%	494,453 Common Stock
Jan 29 2021	BUY Grant, award, or other acquisition	$216,303 $35.24 p/Share	6,138 Added 1.22%	497,194 Common Stock
Jan 01 2021	SELL Payment of exercise price or tax liability	$15,610 $24.7 p/Share	632 Reduced 0.13%	491,056 Common Stock
Dec 31 2020	SELL Payment of exercise price or tax liability	$619,106 $24.7 p/Share	25,065 Reduced 4.85%	491,688 Common Stock

Also insider at

Equillium, Inc. Healthcare

Mark Pruzanski

Director

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ICPT shares.

Notify only if

Value

Insider Trading

Get notified when an Intercept Pharmaceuticals, Inc. insider buys or sells ICPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to INTERCEPT PHARMACEUTICALS, INC.

Account